Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 2, 2023

Primary Completion Date

July 2, 2023

Study Completion Date

July 17, 2023

Conditions

Healthy

Interventions

DRUG

RID-TDS 13.3 mg/24 h

3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period

DRUG

Exelon® 13.3 mg/24 h

11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period

Trial Locations (1)

SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt

All Listed Sponsors

collaborator

SocraTec R&D GmbH

OTHER

collaborator

SocraMetrics GmbH

INDUSTRY

lead

Luye Pharma Group Ltd.

INDUSTRY

NCT05853341 - Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h) | Biotech Hunter | Biotech Hunter